SCHEMBL7366720

SCHEMBL7366720

C1=CN=CC=NC=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7366713 1.00
SCHEMBL31676163 0.91
SCHEMBL18320895 0.82
SCHEMBL460688 0.82
SCHEMBL30401686 0.82
SCHEMBL460689 0.82
SCHEMBL31675822 0.82
SCHEMBL12079525 0.80
SCHEMBL12079523 0.80
Hydrochloric Acid SCHEMBL38657456 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104080335-B Some chemical entities, composition and method 钱向平 2017-06-09 CN claimed
EP-4628519-A1 ORGANOGERMANIUM(IV) CARBOXYLATES AND MIXTURES OF GERMANIUM CARBOXYLATES WITH ORGANIC ACID ANHYDRIDES AS CATALYSTS Technische Universität Graz (AT) 2025-10-08 EP disclosed
WO-2025151449-A1 BIFUNCTIONAL P53-BINDING COMPOUNDS AND USES THEREOF PHOTYS THERAPEUTICS, INC. (US) 2025-07-17 WO disclosed
WO-2024218499-A1 HETEROCYCLIC INHIBITORS OF DNA POLYMERASE THETA FOR THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2024-10-24 WO disclosed
EP-4419526-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2024-08-28 EP disclosed
EP-4419527-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2024-08-28 EP disclosed
WO-2023165987-A1 PRECURSOR MARKERS AND RADIOTRACERS WITH THREE OR MORE TARGETING VECTORS FOR THERANOSTICS USED IN NUCLEAR MEDICINE Atoms for Cure GmbH (DE) 2023-09-07 WO disclosed
US-20230242546-A1 SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS SUDO BIOSCIENCES LIMITED (GB) 2023-08-03 US disclosed
WO-2023118195-A1 FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS Atoms for Cure GmbH (DE) 2023-06-29 WO disclosed
WO-2023067356-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 WO disclosed
US-20170217930-A1 PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES BRISTOL-MEYERS SQUIBB COMPANY (US) 2017-08-03 US disclosed
CN-104080335-B Some chemical entities, composition and method 钱向平 2017-06-09 CN disclosed
EP-2457913-B1 Heteroaryl compounds, compositions thereof, and methods of treatment therewith SIGNAL PHARM LLC (US) 2017-04-19 EP disclosed
EP-1973887-B1 AZA HETEROCYCLICS FOR THE TREATMENT OF MALARIA OR AIDS IMMUPHARMA FRANCE SA (FR) 2012-09-19 EP disclosed
US-5539104-A 1,4 Diazocines as fibrinogen antagonists SMITHKLINE BEECHAM CORP. (US) 1996-07-23 US disclosed
US-5539104-A 1,4 Diazocines as fibrinogen antagonists SMITHKLINE BEECHAM CORP. (US) 1996-07-23 US disclosed
EP-0610432-A1 C8-CYCLIC PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-08-17 EP disclosed
EP-0610432-A1 C8-CYCLIC PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-08-17 EP disclosed
WO-1993009133-A1 C8-CYCLIC PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1993-05-13 WO disclosed
WO-1993009133-A1 C8-CYCLIC PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1993-05-13 WO disclosed